Improving insulin sensitivity, liver steatosis and fibrosis in type 2 diabetes by a food-based digital education-assisted lifestyle intervention program: a feasibility study.
Diabetes management
Digital education
Insulin sensitivity
Non-alcoholic fatty liver disease
Type 2 diabetes
Journal
European journal of nutrition
ISSN: 1436-6215
Titre abrégé: Eur J Nutr
Pays: Germany
ID NLM: 100888704
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
26
08
2020
accepted:
16
02
2021
pubmed:
12
4
2021
medline:
16
9
2021
entrez:
11
4
2021
Statut:
ppublish
Résumé
Recent trials demonstrated remission of type 2 diabetes and non-alcoholic fatty liver disease (NAFLD) following formula diet-induced weight loss. To improve the outreach for populations in need, many mobile health apps targeting weight loss have been developed with limited scientific evaluation of these apps. The present feasibility study investigated the effects of a novel approach incorporating a regular 'whole food-based' low-calorie diet combined with app-based digital education and behavioral change program on glucose metabolism and disease management. Twenty-four individuals with type 2 diabetes followed this approach supported by weekly coaching calls for 12 weeks. Phenotyping included bioimpedance analysis, mixed-meal tolerance test, magnetic resonance spectroscopy and transient elastography for assessing liver fat content and liver stiffness. Over 12 weeks, participants reduced their body weight by 9% (97 ± 13 to 88 ± 12 kg), body mass index (BMI; 33 ± 5 to 29 ± 4 kg/m This novel approach combining digital education with a low-calorie diet results in effective improvements of body weight, glycemic control and NAFLD and could complement existing care for patients with type 2 diabetes. NCT04509245.
Identifiants
pubmed: 33839905
doi: 10.1007/s00394-021-02521-3
pii: 10.1007/s00394-021-02521-3
pmc: PMC8437928
doi:
Banques de données
ClinicalTrials.gov
['NCT04509245']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3811-3818Informations de copyright
© 2021. The Author(s).
Références
CMAJ. 2020 Aug 4;192(31):E875-E891
pubmed: 32753461
J Pers Med. 2019 Jun 07;9(2):
pubmed: 31181705
Lancet. 2018 Feb 10;391(10120):541-551
pubmed: 29221645
Trends Endocrinol Metab. 2019 Oct;30(10):701-709
pubmed: 31422872
J Clin Invest. 2017 Feb 1;127(2):695-708
pubmed: 28112681
Cardiovasc Diabetol. 2016 Apr 07;15:59
pubmed: 27053136
Eur Heart J. 2020 Jan 7;41(2):231-238
pubmed: 30590564
Int J Obes Relat Metab Disord. 2004 Jan;28(1):113-9
pubmed: 14569279
Diabetes Care. 2019 May;42(5):731-754
pubmed: 31000505
Hepatology. 2014 Aug;60(2):545-53
pubmed: 24668862
Diabetes Care. 2017 Oct;40(10):e145-e146
pubmed: 28774944
Diabetes. 2005 Mar;54(3):603-8
pubmed: 15734833
Gastroenterology. 2020 May;158(7):1851-1864
pubmed: 32061595
Clin Liver Dis (Hoboken). 2020 May 07;15(4):144-148
pubmed: 32395240
Am J Prev Med. 2019 Jun;56(6):894-903
pubmed: 31003801
Nature. 2019 Dec;576(7785):51-60
pubmed: 31802013
Mol Metab. 2021 Aug;50:101122
pubmed: 33220492
J Hepatol. 2021 May;74(5):1028-1037
pubmed: 33259845
Diabetes Care. 2020 Sep;43(9):2161-2168
pubmed: 32910776
Adv Nutr. 2018 Jan 1;9(1):30-40
pubmed: 29438460
Diabetes Care. 2013 Feb;36(2):195-201
pubmed: 23111058
Metabolism. 2014 Apr;63(4):554-61
pubmed: 24559843
Hepatology. 2017 May;65(5):1557-1565
pubmed: 28130788
Hepatology. 2016 Jun;63(6):1817-27
pubmed: 26659452
Diabetes Care. 2021 Jan;44(Suppl 1):S100-S110
pubmed: 33298419
Magn Reson Med. 2014 May;71(5):1670-5
pubmed: 23798380
Cell Metab. 2018 Oct 2;28(4):547-556.e3
pubmed: 30078554
Lancet Diabetes Endocrinol. 2019 Sep;7(9):684-694
pubmed: 31345776
Diabetes Care. 2019 Jan;42(Suppl 1):S81-S89
pubmed: 30559234
J Clin Endocrinol Metab. 2010 Dec;95(12):5412-8
pubmed: 20843953
Obes Facts. 2016;9(2):65-90
pubmed: 27055256
Front Endocrinol (Lausanne). 2020 Jun 24;11:412
pubmed: 32670197
J Hepatol. 2017 Oct;67(4):829-846
pubmed: 28545937